Drug Trial Radar · NCT06521567
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
83
Planned (sponsor's estimate)
Start
Mar 6, 2025
Primary completion
Oct 13, 2026
Study completion Oct 13, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants
Conditions
- Melanoma
- Hodgkin Lymphoma
- High and Low Grade Glioma
- Glioblastoma Multiforme (GBM)
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Ependymoma
- Osteosarcoma
- Hepatic Tumors
- Hepatoblastoma
- Hepatocellular Carcinoma (HCC)
- Fibrolamellar Carcinoma
- Rhabdomyosarcoma
Interventions
CobolimabDrug
Cobolimab will be administered
DostarlimabDrug
Dostarlimab will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1- Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 42 days
- Part 1- Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs) and adverse events (AEs) leading to discontinuation occurring during the studyTime frame: Up to approximately 46 months
- Part 1- Serum concentration of CobolimabTime frame: 1±0.5 hours (h) post-dose on Cycle 1 Day 1; 168±12 h post-dose Cycle 1Day 8; Pre-dose and 1±0.5 h post-dose on Cycle 2 Day 1; Cycle 4 Day 1 and Cycle 6 Day 1(Each cycle is of 21 days)
- Part 1- Serum concentration of DostarlimabTime frame: 1±0.5 h post start of cobolimab infusion on Cycle 1 Day 1; Pre-dose on Cycle 2 Day 1; Cycle 4 Day 1 and Cycle 6 Day 1(Each cycle is of 21 days)
- Part 1- Recommended Phase 2 Dose (RP2D) of Cobolimab and Dostarlimab combinationTime frame: Up to approximately 12 months
- Part 2- Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 46 months
- Part 2- Number of participants with TEAEs, SAEs, imAEs, TEAEs leading to death and AEs leading to discontinuationTime frame: Up to approximately 46 months
- Part 2-Number of participants with changes in laboratory parameters, vital signs and cardiac parametersTime frame: Up to approximately 46 months
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
Hackensack, New Jersey
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Providence, Rhode Island
GSK Investigational Site
Madison, Wisconsin
GSK Investigational Site
Brno, Czechia
GSK Investigational Site
Phaha 5, Czechia
GSK Investigational Site
Copenhagen, Denmark
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Strasbourg, France
GSK Investigational Site
Villejuif, France
GSK Investigational Site
Bologna, Italy
GSK Investigational Site
Naples, Italy
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.